Title : Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.

Pub. Date : 2021 Sep

PMID : 34224367






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of mTORC1 signaling has been shown to diminish growth of meningiomas and schwannomas in preclinical studies, and clinical data suggest that everolimus, an orally administered mTORC1 inhibitor, may slow tumor progression in a subset of NF2 patients with vestibular schwannoma (VS). Everolimus CREB regulated transcription coactivator 1 Mus musculus
2 These data may explain the limited anti-tumor effect of everolimus observed in clinical studies for NF2 patients and will inform the design of future pre-clinical and clinical studies targeting mTORC1 in meningiomas and schwannomas. Everolimus CREB regulated transcription coactivator 1 Mus musculus